Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

This is a long-term, multicenter, open-label trial designed to examine the long-term safety
and tolerability of brexpiprazole in adolescent subjects (ages 13-17) with a DSM-5 diagnosis
of schizophrenia.

Inclusion Criteria:

- Male & female subjects 13-17 years of age, inclusive.

- Subjects who turn 18 during trial 331-10-234 are permitted in this trial.

- Subjects with a current primary diagnosis of schizophrenia, as defined by Diagnostic
and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria and confirmed
by the K-SADS-PL completed at time of entry into Trial 331-10-234. For de novo
subjects, the current diagnosis of schizophrenia must be confirmed by the K-SADS-PL at
screening.

- Subjects who, in the investigator's judgment, require treatment with antipsychotic
medication(s).

Exclusion Criteria:

- Subjects with a DSM-5 diagnosis other than schizophrenia that has been the primary
focus of treatment within 3 months of screening

- Subjects with a clinical presentation or history that is consistent with delirium,
dementia, amnesia, or other cognitive disorders; subjects with psychotic symptoms that
are better accounted for by another general medical condition(s) or direct effect of a
substance (e.g., medication, illicit drug use).

- History of failure of clozapine treatment or response to clozapine treatment only.

- History of neuroleptic malignant syndrome